Chugai Files For Japan Approval Of Melanoma Drug Vemurafenib
This article was originally published in PharmAsia News
Executive Summary
Chugai has filed for the Japan approval of its oral BRAF kinase inhibitor vemurafenib in the treatment of BRAF V600 genetic mutation malignant melanoma, the company announced on April 9.